Targeting Aberrant p70S6K Activation for Estrogen Receptor–Negative Breast Cancer Prevention
Authors:
- 31 October 2017
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 10 (11) , 641-650
Abstract
The prevention of estrogen receptor–negative (ER−) breast cancer remains a major challenge in the cancer prevention field, although antiestrogen and aromatase inhibitors have shown adequate efficacy in preventing estrogen receptor–positive (ER+) breast cancer. Lack of commonly expressed, druggable targets is a major obstacle for meeting this challenge. Previously, we detected the activation of Akt signaling pathway in atypical hyperplasic early-stage lesions of patients. In the current study, we found that Akt and the downstream 70 kDa ribosomal protein S6 kinase (p70S6K) signaling pathway was highly activated in ER− premalignant breast lesions and ER− breast cancer. In addition, p70S6K activation induced transformation of ER− human mammary epithelial cells (hMEC). Therefore, we explored the potential of targeting Akt/p70S6K in the p70S6K activated, ER− hMEC models and mouse mammary tumor models for the prevention of ER− breast cancer. We found that a clinically applicable Akt/p70S6K dual inhibitor, LY2780301, drastically decreased proliferation of hMECs with ErbB2-induced p70S6K activation via Cyclin B1 inhibition and cell-cycle blockade at G0–G1 phase, while it did not significantly reverse the abnormal acinar morphology of these hMECs. In addition, a brief treatment of LY2780301 in MMTV-neu mice that developed atypical hyperplasia (ADH) and mammary intraepithelial neoplasia (MIN) lesions with activated p70S6K was sufficient to suppress S6 phosphorylation and decrease cell proliferation in hyperplasic MECs. In summary, targeting the aberrant Akt/p70S6K activation in ER− hMEC models in vitro and in the MMTV-neu transgenic mouse model in vivo effectively inhibited Akt/S6K signaling and reduced proliferation of hMECs in vitro and ADH/MIN lesions in vivo, indicating its potential in prevention of p70S6K activated ER− breast cancer. Cancer Prev Res; 10(11); 641–50. ©2017 AACR.Keywords
Funding Information
- Susan G. Komen Breast Cancer Foundation (KG091020)
- Susan G. Komen Breast Cancer Foundation (RO1-CA184836)
- Susan G. Komen Breast Cancer Foundation (RO1-CA112567-06)
- Susan G. Komen Breast Cancer Foundation (R01CA208213)
- MD Anderson Cancer Center (CA016672)
This publication has 44 references indexed in Scilit:
- Prevention of ER-negative breast cancerEuropean Journal Of Cancer Prevention, 2012
- Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancerBreast Cancer Research, 2011
- Chemoprevention of Hormone Receptor-Negative Breast Cancer: New Approaches Needed2010
- Identification of Novel Kinase Targets for the Treatment of Estrogen Receptor–Negative Breast CancerClinical Cancer Research, 2009
- 14-3-3ζ Cooperates with ErbB2 to Promote Ductal Carcinoma In Situ Progression to Invasive Breast Cancer by Inducing Epithelial-Mesenchymal TransitionCancer Cell, 2009
- Effect of Lapatinib on the Development of Estrogen Receptor–Negative Mammary Tumors in MiceJNCI: Journal of the National Cancer Institute, 2009
- Chapter 2 PI3K/PTEN Signaling in Angiogenesis and Tumorigenesis2009
- PI3K pathway alterations in cancer: variations on a themeOncogene, 2008
- Deciphering downstream gene targets of PI3K/mTOR/p70S6K pathway in breast cancerBMC Genomics, 2008
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences of the United States of America, 2005